AR084373A1 - Composiciones y metodos para la eliminacion de biopeliculas - Google Patents

Composiciones y metodos para la eliminacion de biopeliculas

Info

Publication number
AR084373A1
AR084373A1 ARP110101015A ARP110101015A AR084373A1 AR 084373 A1 AR084373 A1 AR 084373A1 AR P110101015 A ARP110101015 A AR P110101015A AR P110101015 A ARP110101015 A AR P110101015A AR 084373 A1 AR084373 A1 AR 084373A1
Authority
AR
Argentina
Prior art keywords
protein
microbial dna
polypeptide
dnabii
bacteria
Prior art date
Application number
ARP110101015A
Other languages
English (en)
Inventor
Steven D Goodman
Lauren O Bakaletz
Original Assignee
Univ Southern California
Res Inst At Nationwide Children’S Hospital Ct For Microbial Pathogenesis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California, Res Inst At Nationwide Children’S Hospital Ct For Microbial Pathogenesis filed Critical Univ Southern California
Publication of AR084373A1 publication Critical patent/AR084373A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1242—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente provee polipéptidos aislados o recombinantes que son de utilidad para vacunar a individuos que padecen de la enfermedad por biopelículas crónica/recurrente o como un agente terapéutico para aquellos que tienen una infección existente. El sistema inmune del individuo generará luego naturalmente anticuerpos que evitan o desalojan estas bacterias del huésped interfiriendo con la construcción y/o la manutención de una biopelícula de protección funcional. De modo alternativo, los anticuerpos se pueden administrar a los polipéptidos para tratar o prevenir la infección. Las bacterias que no forman biopelículas funcionales son desalojadas más fácilmente por el resto del sistema inmune del huésped.Reivindicación 1: Un método de inhibición, competencia o titulación de la unión de un polipéptido o proteína DNABII con un ADN microbiano, que comprende poner en contacto el polipéptido o proteína DNABII o el ADN microbiano con un agente de interferencia, inhibiendo, compitiendo o titulación de la unión de la proteína o polipéptido DNABII con el ADN microbiano.
ARP110101015A 2010-03-29 2011-03-28 Composiciones y metodos para la eliminacion de biopeliculas AR084373A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31874310P 2010-03-29 2010-03-29
US34736210P 2010-05-21 2010-05-21
US39789110P 2010-06-16 2010-06-16
US201161454972P 2011-03-21 2011-03-21

Publications (1)

Publication Number Publication Date
AR084373A1 true AR084373A1 (es) 2013-05-15

Family

ID=44656747

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101015A AR084373A1 (es) 2010-03-29 2011-03-28 Composiciones y metodos para la eliminacion de biopeliculas

Country Status (13)

Country Link
US (2) US8999291B2 (es)
EP (1) EP2552944B1 (es)
JP (3) JP6351972B2 (es)
KR (1) KR20130040173A (es)
CN (2) CN103097399A (es)
AR (1) AR084373A1 (es)
AU (1) AU2011235296C1 (es)
CA (1) CA2794305C (es)
ES (1) ES2754240T3 (es)
IL (2) IL222076B (es)
MX (1) MX2012010793A (es)
SG (1) SG183816A1 (es)
WO (1) WO2011123396A1 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR084373A1 (es) 2010-03-29 2013-05-15 Univ Southern California Composiciones y metodos para la eliminacion de biopeliculas
CA2810851C (en) * 2010-09-09 2022-08-02 University Of Southern California Compositions and methods for the removal of biofilms comprising a high-mobility group-box (hmg-box) domain containing polypeptide
US10010568B2 (en) 2011-02-04 2018-07-03 Katherine Rose Kovarik Method and system for reducing the likelihood of a spirochetes infection in a human being
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US10111913B2 (en) 2011-02-04 2018-10-30 Joseph E. Kovarik Method of reducing the likelihood of skin cancer in an individual human being
US11191665B2 (en) 2011-02-04 2021-12-07 Joseph E. Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US10583033B2 (en) 2011-02-04 2020-03-10 Katherine Rose Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US10835560B2 (en) 2013-12-20 2020-11-17 Joseph E. Kovarik Reducing the likelihood of skin cancer in an individual human being
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US10085938B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for preventing sore throat in humans
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11357722B2 (en) 2011-02-04 2022-06-14 Seed Health, Inc. Method and system for preventing sore throat in humans
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US20140023618A1 (en) * 2012-07-23 2014-01-23 Applied Biology Systems and methods for treatment of androgenetic skin conditions by microbial organisms
EP2964257A4 (en) 2013-03-08 2016-10-26 Res Inst Nationwide Childrens Hospital TRANSCUTANEOUS DOSE FORMULATION
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
ES2746971T3 (es) * 2013-06-13 2020-03-09 Res Inst Nationwide Childrens Hospital Composiciones y procedimientos para el tratamiento de infecciones por burkholderia
US9745366B2 (en) * 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
US20150086561A1 (en) 2013-09-26 2015-03-26 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
EP3693015A1 (en) 2014-01-13 2020-08-12 Trellis Bioscience, LLC Binding moieties for biofilm remediation
EP3536168A3 (en) * 2014-03-06 2019-10-16 The Research Institute at Nationwide Children's Hospital Probiotic formulations and methods for use
US10624934B2 (en) 2014-03-06 2020-04-21 Research Institute At Nationwide Children's Hospital Prebiotic formulations
WO2016100712A1 (en) * 2014-12-18 2016-06-23 Rhode Island Hospital Visualization of bacterial colonization and biofilm formation on orthopaedic trauma explants
US20180207067A1 (en) 2015-07-14 2018-07-26 Research Institute at Nationwide Children's Hospit al Novel formulation for the elimination of cariogenic and opportunistic pathogens within the oral cavity
AU2016303688B2 (en) 2015-07-31 2023-06-15 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
EP3362168A1 (en) * 2015-10-14 2018-08-22 Novozymes A/S Cleaning of water filtration membranes
EP3365027B1 (en) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
US10568916B2 (en) 2015-11-30 2020-02-25 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US10933128B2 (en) 2015-11-30 2021-03-02 Joseph E. Kovarik Method and system for protecting honey bees from pesticides
US10675347B2 (en) 2015-11-30 2020-06-09 Joseph E. Kovarik Method and system for protecting honey bees from fipronil pesticides
US11529412B2 (en) 2015-11-30 2022-12-20 Seed Health, Inc. Method and system for protecting honey bees from pesticides
US10086024B2 (en) 2015-11-30 2018-10-02 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
AR107395A1 (es) * 2016-01-19 2018-04-25 Monsanto Technology Llc Proteínas anti-microbianas
WO2017145142A1 (en) 2016-02-25 2017-08-31 Nobio Ltd. Micro and nanoparticulate compositions comprising anti-microbially active groups
WO2017192594A1 (en) * 2016-05-02 2017-11-09 Trellis Bioscience, Llc Binding moieties for biofilm remediation
AU2018206552A1 (en) * 2017-01-04 2019-07-18 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
AU2018206560A1 (en) * 2017-01-04 2019-07-18 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
EP3595445A1 (en) 2017-03-15 2020-01-22 The Research Institute at Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
BR112020004157A2 (pt) 2017-08-30 2020-09-08 Nobio Ltd. composições e dispositivos médicos compreendendo partículas antimicrobianas
WO2019226978A1 (en) * 2018-05-25 2019-11-28 Temple University-Of The Commonwealth System Of Higher Education Eradication of bacterial biofilm using anti-amyloid monoclonal antibodies
USD908214S1 (en) 2018-07-10 2021-01-19 United States Endoscopy Group, Inc. Tip protector
KR20210070331A (ko) * 2018-10-05 2021-06-14 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 생물막 제거를 위한 hmgb1 단백질 유도체
CA3114925A1 (en) * 2018-10-05 2020-04-09 Research Institute At Nationwide Children's Hospital Compositions and methods for enzymatic disruption of bacterial biofilms
KR102059892B1 (ko) * 2019-01-24 2019-12-27 에코바이오홀딩스 주식회사 황화수소 제거용 미생물 군집 및 이의 용도
EP3997120A4 (en) 2019-07-08 2023-11-22 Research Institute at Nationwide Children's Hospital ANTIBODY COMPOSITIONS FOR DISRUPTING BIOFILM
US20210403976A1 (en) * 2020-06-30 2021-12-30 Research Institute At Nationwide Children's Hospital Methods for determining antibiotic sensitivity
JP2023533504A (ja) * 2020-07-07 2023-08-03 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルムの処置および予防のための併用療法
CN113637051A (zh) * 2021-08-10 2021-11-12 昆明医科大学 一种具有预防和远期改善阿尔兹海默症症状的多肽及其应用
WO2023164114A2 (en) * 2022-02-24 2023-08-31 The Research Institute At Nationwide Children's Hospital Bacterial biofilm inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US20030139327A9 (en) 2000-01-31 2003-07-24 Rosen Craig A. Nucleic acids, proteins, and antibodies
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
US20030099602A1 (en) * 2001-10-25 2003-05-29 Levin Gilbert V. D-tagatose as an anti-biofilm agent
CA2493977A1 (en) * 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine composition comprising lipooligosaccharide with reduced phase variability
GB0226251D0 (en) 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
US20060121047A1 (en) 2002-11-20 2006-06-08 Tracey Kevin J Use of hmgb polypetides for increasing immune responses
EP1592707A2 (en) 2003-02-14 2005-11-09 Fondazione Centro San Raffaele Del Monte Tabor Hmgb1 modulator binding domain
WO2005025604A2 (en) 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
US20080305120A1 (en) 2004-06-17 2008-12-11 Medimmune, Inc. Immunogenic Compositions Comprising Hmgb 1 Polypeptides
US20060030539A1 (en) * 2004-08-06 2006-02-09 National Jewish Medical And Research Center Product and process for inhibition of biofilm development
CN101132811B (zh) * 2004-10-22 2012-05-30 米迪缪尼有限公司 抗hmgb1的高亲和力抗体及其用法
US20060228384A1 (en) * 2005-04-06 2006-10-12 Sequoia Sciences, Inc. Control of biofilm with a biofilm inhibitor
WO2006114805A2 (en) 2005-04-28 2006-11-02 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb2 and hmgb3 proteins for medical applications
AR084373A1 (es) 2010-03-29 2013-05-15 Univ Southern California Composiciones y metodos para la eliminacion de biopeliculas
CA2810851C (en) 2010-09-09 2022-08-02 University Of Southern California Compositions and methods for the removal of biofilms comprising a high-mobility group-box (hmg-box) domain containing polypeptide
ES2746971T3 (es) 2013-06-13 2020-03-09 Res Inst Nationwide Childrens Hospital Composiciones y procedimientos para el tratamiento de infecciones por burkholderia

Also Published As

Publication number Publication date
CA2794305A1 (en) 2011-10-06
CN103097399A (zh) 2013-05-08
AU2011235296B2 (en) 2015-09-17
WO2011123396A1 (en) 2011-10-06
IL263729A (en) 2019-01-31
AU2011235296C1 (en) 2017-05-04
CN107096025A (zh) 2017-08-29
US20110236306A1 (en) 2011-09-29
JP6351972B2 (ja) 2018-07-04
US20150166641A1 (en) 2015-06-18
IL222076B (en) 2018-12-31
CA2794305C (en) 2023-10-10
AU2011235296A1 (en) 2012-10-18
JP6728257B2 (ja) 2020-07-22
JP2016178944A (ja) 2016-10-13
EP2552944B1 (en) 2019-08-14
ES2754240T3 (es) 2020-04-16
JP2018086029A (ja) 2018-06-07
US8999291B2 (en) 2015-04-07
SG183816A1 (en) 2012-10-30
MX2012010793A (es) 2013-05-09
EP2552944A1 (en) 2013-02-06
JP2013529893A (ja) 2013-07-25
KR20130040173A (ko) 2013-04-23

Similar Documents

Publication Publication Date Title
AR084373A1 (es) Composiciones y metodos para la eliminacion de biopeliculas
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
EA201200793A1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
BR112017028353A2 (pt) anticorpos para cd40 com atividade agonista melhorada
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
BR112014012607A2 (pt) métodos de tratamento usando um inibidor de interferon gama
UA115034C2 (uk) Імунокон'югат для застосування в лікуванні раку або запального порушення
EA201300137A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями
UA112743C2 (uk) Терапевтичний dll4-зв'язувальний білок
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
UA113397C2 (xx) Попередження несприятливих ефектів, спричинених специфічними доменами зв'язування cd3
BR112012002124A2 (pt) tratamento da doença de crohn com laquinimode.
BR112012018132A2 (pt) "marcadores de células - tronco tumorais e uso dos mesmos".
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201500802A1 (ru) Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы
WO2012149478A3 (en) Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
AR062268A1 (es) Agentes ligantes direccionados dirigidos a pdgfr-alfa y sus usos
EA201390704A1 (ru) Соединения, ингибирующие металлоферменты
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
EA201201113A1 (ru) Способы и соединения для роста мышц
BR112014027905A2 (pt) anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico.
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
ITTO20110634A1 (it) Metodo per trattare patologie organiche del sistema nervoso, la sindrome psicoorganica e l'encefalopatia

Legal Events

Date Code Title Description
FB Suspension of granting procedure